Myelofibrosis Latest Advances
Find the Latest Research About Myelofibrosis
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9134 publications
Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms.
Journal: bioRxiv : the preprint server for biology
Published: October 23, 2026
High-normal and mildly elevated bilirubin levels in prefibrotic primary myelofibrosis patients are associated with lower thrombotic risk.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: October 16, 2026
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2026
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.
Journal: Leukemia & lymphoma
Published: October 07, 2026
Study on the Effect of Treatment Regiman Combined with Ruxolitinib on MPN Patients with Myelofibrosis and the Influencing Factors of Mutated Gene Load
Journal: Zhongguo shi yan xue ye xue za zhi
Published: September 28, 2026
Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms.
Journal: Cancers
Published: September 28, 2026
Reply to: Comment on "iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation".
Journal: Transplantation and cellular therapy
Published: September 21, 2026
Comment on "iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation".
Journal: Transplantation and cellular therapy
Published: September 19, 2026
Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval.
Journal: Expert review of hematology
Published: September 12, 2026
Last Updated: 11/08/2026